Sunshine Biopharma Inc reports results for the quarter ended in March - Earnings Summary

Sunshine Biopharma

20/05/2024 21:47

* Sunshine Biopharma Inc  SBFM.OQ  reported a quarterly
adjusted
loss of $2.00​​ per share for the quarter ended in March.  The
lone analyst forecast for the quarter was for a loss of $1.04
per share. 
    * Revenue was $7.54 million​; analysts expected $7.00
million. 
    * Sunshine Biopharma Inc's reported EPS for the quarter was
a loss
of $2.00​.
    * The company reported a quarterly loss of $1.28 million.
    * Sunshine Biopharma Inc shares had fallen by 84.6% this
quarter and lost 96.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 87% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Sunshine
Biopharma Inc is $15.00 
This summary was machine generated from LSEG data May 20 at
08:47 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -1.04          -2.00          Missed
 Dec. 31 2023      -3.00          -5.00          Missed
 Sep. 30 2023      -6.00          -4.00          Beat